These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6256890)

  • 21. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
    Huang JH; Hsu RB
    Scand J Infect Dis; 2008; 40(6-7):462-7. PubMed ID: 18584532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence of less severe aortic valve destruction after treatment of experimental staphylococcal endocarditis with vancomycin and dexamethasone.
    Siaperas P; Pefanis A; Iliopoulos D; Katsarolis I; Kyroudi-Voulgari A; Donta I; Karayiannakos P; Giamarellou H
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3531-7. PubMed ID: 11709335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical usefulness of vancomycin.
    Cunha BA; Ristuccia AM
    Clin Pharm; 1983; 2(5):417-24. PubMed ID: 6354567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia.
    Naimi TS; Anderson D; O'Boyle C; Boxrud DJ; Johnson SK; Tenover FC; Lynfield R
    Clin Infect Dis; 2003 Jun; 36(12):1609-12. PubMed ID: 12802763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Staphylococcus aureus with reduced susceptibility to vancomycin in a dialysis graft.
    Perla RJ; Knutson EL; Fontana JL
    Clin Infect Dis; 2005 Aug; 41(4):566-7. PubMed ID: 16028171
    [No Abstract]   [Full Text] [Related]  

  • 27. The role of vancomycin in the treatment paradigm.
    Stevens DL
    Clin Infect Dis; 2006 Jan; 42 Suppl 1():S51-7. PubMed ID: 16323121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
    Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of severe infections caused by Staphylococcus aureus: a change in the vancomycin paradigm?
    Aranha Camargo LF
    Shock; 2008 Oct; 30 Suppl 1():67-9. PubMed ID: 18704006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Key considerations in the treatment of complicated staphylococcal infections.
    Jones RN
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.
    Woods CW; Cheng AC; Fowler VG; Moorefield M; Frederick J; Sakoulas G; Meka VG; Tenover FC; Zwadyk P; Wilson KH
    Clin Infect Dis; 2004 Apr; 38(8):1188-91. PubMed ID: 15095227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection.
    Schrenzel J; Harbarth S; Schockmel G; Genné D; Bregenzer T; Flueckiger U; Petignat C; Jacobs F; Francioli P; Zimmerli W; Lew DP;
    Clin Infect Dis; 2004 Nov; 39(9):1285-92. PubMed ID: 15494904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Staph with lower vancomycin resistance in US.
    OR Manager; 1997 Oct; 13(10):7. PubMed ID: 10174189
    [No Abstract]   [Full Text] [Related]  

  • 34. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin.
    Burnie J; Matthews R; Jiman-Fatami A; Gottardello P; Hodgetts S; D'arcy S
    Clin Infect Dis; 2000 Sep; 31(3):684-9. PubMed ID: 11017816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections.
    Adra M; Lawrence KR
    Ann Pharmacother; 2004 Feb; 38(2):338-41. PubMed ID: 14742775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.
    Rouse MS; Piper KE; Jacobson M; Jacofsky DJ; Steckelberg JM; Patel R
    J Antimicrob Chemother; 2006 Feb; 57(2):301-5. PubMed ID: 16361330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Sep; 46(35):813-5. PubMed ID: 9310213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Introduction to vancomycin.
    Griffith RS
    Rev Infect Dis; 1981; 3 suppl():S200-4. PubMed ID: 7043707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency.
    Pai MP; Mercier RC; Allen SE
    Ann Pharmacother; 2006 Mar; 40(3):553-8. PubMed ID: 16507618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
    Sakoulas G; Moellering RC
    Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.